A three-year, 720-patient study designed to investigate whether
Pfizer/Eisai's acetylcholinesterase inhibitor, Aricept (donepezil), vitamin
E, or placebo can delay the conversion of patients with mild cognitive
impairment to Alzheimer's disease is ongoing. Study details are at
http://www-alz.ucsd.edu/study/study-mc.vep. Stay tuned!
Also, note the expert panel Consensus Paper on Mild Cognitive Impairment
that has been presented to the European Parliament. That one has apparently
not been posted on the net, but an abridged print version should still be
available from UCB Pharma in Brussels (Fax: +32 2/559 93 66).
--HM
"emooky" <emooky at popsmail.com> wrote in message
news:9dakvg$105$1 at news2-2.kornet.net...
> I need your knowledge about that.
>>